About This Webinar
Predicting drug-induced liver injury (DILI) remains a persistent challenge in drug development. Complex, species-specific mechanisms and late-emerging toxicity can hinder preclinical safety assessment and reduce confidence in translational predictions. Advances in liver microphysiological systems (MPS) now offer more physiologically relevant models for evaluating hepatotoxic risk across species and development stages.

In this webinar, Emily Richardson will discuss key strategies for applying adaptable liver MPS across toxicology workflows, from early screening through mechanistic investigation of adverse liver events in humans.

Topics to be covered:
- Common challenges in predicting DILI across development stages
- Use of Liver MPS to unlock complex and latent DILI effects
- Application of Liver MPS for cross-species risk assessment
- Insights from comparative human and preclinical liver model studies
- Considerations for evaluating cholestatic DILI
Presenters
  • 1595863069-9381c1966094975c
    Drug Discovery News Webinars
  • 1769791227-e90084afcc3e4fe0
    Emily Richardson, PhD
    Biology Group Leader, CN Bio
    Emily Richardson is a biology group leader at CN Bio, overseeing the development of microphysiological systems (MPS) for toxicology and safety assessment. She joined CN Bio in 2020, helping create lung and lung-liver MPS models for infectious disease research and inhaled therapeutics. She holds a degree in biochemistry and molecular medicine from the University of Nottingham and a PhD from the University of Leicester, where her research on 3D cell culture informs her work on predictive human-relevant models.
Powered by BigMarker